Cmputerized tomography (CT) of neck revealed some cervical lymph nodes enlargement. The results of cervical lymph node biopsy indicated tuberculosis lymphadenitis. Thorax CT was normal. The patient was treated with a combination of 5 antituberculosis drugs: pyrazinamide 2500 mg/d, INH 300 mg/d, rifampicin 600 mg/d, and ethambutol 1500 mg/d administered 3 times per week after each hemodialysis treatment, and streptomycin 1g 3 times per week administered 6 to 8 hours before each hemodialysis treatment. Because she experienced hearing and visual loss 2 weeks after the initiation of anti-tuberculosis treatment, therapy with ethambutol and streptomycin was terminated. At that stage, the MR imaging showed no abnormality in the cerebellum and hepatic function tests (aspartat and alanin transaminase) were in normal ranges. Therapy was continued with INH, rifampicin, and pyrazinamide. Two months later, she exhibited a mild intentional tremor and severe truncal ataxia, and she could not stand, sit, or walk without help. The results of motor and sensorial examinations were within normal limits, and no pathologic reflexes were noted. Results of the patient’s cerebrospinal fluid (CSF) analysis revealed a mild elevated protein and a glucose level within the normal range. The results of testing for infectious diseases and cultures of the CSF were also within normal limits. Brain MR imaging showed diffuse cortical hyperintensity in both cerebellar hemispheres and vermis (Figure 1a, b). Anti-tuberculosis therapy was terminated, and treatment with pyridoxine 100 mg/d was initiated. Five months after discharge, a neurologic examination revealed mild ataxia with hearing and visual disturbance. In the follow-up brain MR examinations, cerebellar hyperintensity was persisting on the FLAIR and T2-weighted images.

Click Here to Zoom

Figure 1: Axial T2 (a) and FLAIR (b) weighted images show diffuse cortical increased signal intensity and swelling in both cerebellar hemispheres and vermis.

Although It was well known hepatotoxicity of INH, pyrazinamide and riphampicine, only INH was reported related to neurotoxicity⁶. For this reason, the cerebellar signs of presented patient must be depended on INH.

Isoniazid induces neurotoxicity by inhibiting the phosphorylation of pyridoxine, which results in the decreased production of pyridoxal-5-phosphate, a coenzyme involved in multiple metabolic functions including neurotransmission via gamma-aminobutyric acid (GABA)⁷. Because GABA is the primary inhibitory neurotransmitter produced by cerebellar Purkinje cells, it may be important in patients with cerebellar signs caused by INH toxicity⁵.

It is likely that the increased incidence of INH toxicity in dialysis patients is multifactorial. In these patients, INH toxicity is attributed to malnutrition, pyridoxine deficiency, a reduced degradation rate resulting from slow acetylation, and poor renal clearance of INH⁵. Our patient was well nourished, but her acetylation status was unknown.

Drug- induced cerebellitis is primarily a clinical diagnosis made by the exclusion of other metabolic or infective causes. The close temporal relationship between the onset of cerebellar findings and the initiation of drug therapy and resolution of symptoms after stopping the drug provide strong support for such a diagnosis⁴. Differentiating cerebellar edema caused by drug toxicity from acute cerebellitis is difficult in MR studies. Acute cerebellitis occur as a primary infectious, post-infectious or post-vaccination disorder and mostly presents in early childhood. The most common MR imaging findings in patients with acute cerebellitis are diffuse cerebellar grayand- white matter hyperintense signals on T2-weighted images. The CSF examination may be normal or reveal pleocytosis. Clinical improvement generally precedes that demonstrated on MR imaging. Considerable clinical improvement is shown in the course of time, whereas the MR findings persist. Cerebellar atrophy is seen in the chronic phase of the disease⁸. Because our 50-year-old patient’s clinical findings gradually diminished after the administration of pyridoxine and the discontinuation of isoniasid, her cerebellar signs were attributed to treatment with INH.

In conclusion, a diagnosis of isoniazid -induced cerebellit should be considered when cerebellar signs develop in patients undergoing hemodialysis and treatment with INH. The recognition of that disorder is important because complete or partial recovery is possible after discontinuation of anti-tuberculosis therapy and initiation of pyridoxine therapy.

1) Siskind MS, Thienemann D, Kirlin L. Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature. Nephron 1993;64:303-306.

2) Quantrill SJ, Woodhead MA, Bell CE, Hardy CC, Hutchison AJ, Gokal R.Side-effects of antituberculosis drug treatment in patients with chronic renal failure. Eur Respir J 2002; 20:440-

3) Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003; 16:38-44.

4) Cheung WC, Lo CY, Lo WK, Ip M, Cheng IK. Isoniazid induced encephalopathy in dialysis patients. Tuber Lung Dis 1993; 74:136-139.

5) Blumberg EA, Gil RA. Cerebellar syndrome caused by isoniazid. DICP 1990;24:829-831.

6) Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-todate review. J Gastroenterol Hepatol. 2008 ;23:192-202.

7) Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. Eur J Emerg Med 2005;12:78-85.

8) De Bruecker Y, Claus F, Demaerel P,et al. MRI findings in acute cerebellitis. Eur Radiol 2004; 14:1478-1483.